Novadiscovery
Nova In Silico (Novadiscovery) is a French health technology company that provides the jinkō clinical trial simulation platform, using disease models and digital patient populations to predict drug efficacy and optimize trial design for pharmaceutical companies.
- Company typePrivate
- Founded2010
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Novadiscovery does
Nova In Silico (also branded Novadiscovery) is a French health technology company founded in 2010 and headquartered in Lyon, France, that develops the jinkō clinical trial simulation platform for the pharmaceutical industry. The platform combines data science, biology, and medicine to predict clinical trial outcomes before studies are conducted in human subjects, using computational disease models and virtual patient populations to simulate treatment efficacy, optimize protocol design, and identify responder subgroups. Specific disease models have been developed across therapeutic areas including asthma, hypoparathyroidism, and hepatitis B (HBV), with documented applications spanning drug discovery, clinical development, and market access phases.
The jinkō platform is positioned as the first collaborative clinical trial simulation platform and offers a model library, virtual patient generation, simple protocol design tools, and collaborative curation capabilities. It is complemented by a Digital Twin for Clinical R&D offering that generates virtual populations and simulates disease progression and treatment responses. The company markets the platform as reducing clinical trial duration, minimizing human subject risk, and producing payer-grade evidence packages within months rather than years.
Nova In Silico serves pharmaceutical companies through an enterprise field sales motion with a demo-based acquisition approach. The company generates revenue through SaaS-style subscriptions and project-based engagements with global pharma clients including Takeda (applied to Natpar for hypoparathyroidism) and ENYO Pharma (applied to Vonafexor for HBV across 700+ trial designs). The company also engages in industry positioning through white papers, webinars, and conference participation, and in June 2025 announced a strategic collaboration with Fujitsu to integrate AI-powered simulation capabilities into the platform.
Novadiscovery firmographics
Firmographics- Name
- Novadiscovery
- Legal name
- Nova
- Website
- https://novadiscovery.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nova In Silico (Novadiscovery) is a French health technology company that provides the jinkō clinical trial simulation platform, using disease models and digital patient populations to predict drug efficacy and optimize trial design for pharmaceutical companies.
- Ownership category
- akta.pro rank
Novadiscovery industry classification
Industry- Product category
- Pharmaceutical R&D Software
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industries
- Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI), Site Identification & Feasibility (HLAGACAB), Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where Novadiscovery is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Novadiscovery business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- jinkō Platform Subscription: SaaS-based simulation platform likely offered through subscription model given the enterprise sales motion and demo-based acquisition approach. The platform is described as 'the first collaborative clinical trial simulation platform' suggesting a software-as-a-service delivery model.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Novadiscovery product offering
Product offeringCore offering
Novadiscovery develops and sells jinkō, a collaborative clinical trial simulation platform that uses disease models and digital patients to predict clinical trial outcomes before human testing. The platform enables pharmaceutical companies to design, simulate, and analyze virtual trials across hundreds of protocol variations, supporting applications from target identification through clinical development and market access evidence generation.
Product overview
Nova In Silico (Novadiscovery) operates as a clinical trial simulation company offering jinkō, a cloud-based collaborative simulation platform. The platform is complemented by Digital Twin capabilities for clinical R&D and a library of disease-specific models for virtual patient simulation. The product architecture spans applications from drug discovery through market access, enabling pharmaceutical companies to reduce trial duration, minimize human subject risk, and optimize treatment protocol design through in silico methodologies.
Differentiator
Problem solved
Functional benefit
Brands
- jinkō: The first collaborative clinical trial simulation platform that streamlines clinical trials using disease models and digital patients, predicting clinical outcomes before trials in human subjects.
Products and services
- jinkō Simulation Platform A collaborative clinical trial simulation SaaS platform that combines data science, biology, and medicine to predict clinical outcomes before trials in human subjects. Features include a model library with virtual patients, simple protocol design, knowledge management and collaborative curation, and an intuitive analysis interface for clinical trial experts. Sold to large pharmaceutical companies for protocol optimization, responder identification, and payer evidence generation.
Quantifiable outcome
- Reduce clinical trial duration and number of experiments
- +3 more outcomes
Companies that use Novadiscovery
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Novadiscovery technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Novadiscovery partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- FujitsucoreNova In Silico announced collaboration with Fujitsu on June 24, 2025 to transform clinical trials through advanced AI-powered simulations. This partnership aims to leverage Fujitsu's technology capabilities with NovaDiscovery's jinkō simulation platform to enhance clinical trial design and execution using artificial intelligence.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Novadiscovery competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat4 records
Key highlights7 records
Customer concentration
Novadiscovery social profiles
Digital presenceNovadiscovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novadiscovery leadership team
Management profileNumber of profiles
Novadiscovery funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novadiscovery M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novadiscovery
What does Novadiscovery do?
Novadiscovery develops and sells jinkō, a collaborative clinical trial simulation platform that uses disease models and digital patients to predict clinical trial outcomes before human testing. The platform enables pharmaceutical companies to design, simulate, and analyze virtual trials across hundreds of protocol variations, supporting applications from target identification through clinical development and market access evidence generation.
Is Novadiscovery a public or private company?
Novadiscovery is a private company. It is classified as venture growth investor backed and is currently operating.
When was Novadiscovery founded?
Novadiscovery was founded in 2010. It employs 11 to 50 people.
Where is Novadiscovery based?
Novadiscovery is headquartered in Lyon, France, in the Europe region.
How does Novadiscovery make money?
One revenue line is on record: jinkō Platform Subscription.
Does Novadiscovery have an API?
No public API is recorded for Novadiscovery.
What industry is Novadiscovery in?
Novadiscovery's product category is Pharmaceutical R&D Software. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials). Its NAICS code is 5417 and its SIC code is 8731.